Clinical trials: G-CHOP Chemotherapy
Non-Hodgkin's Lymphoma
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
The domestic standards of G-CSF permit the use of the G-CSF only when the ANC(absolute neutrophil count) drops to 1,000/uL or below. Therefore it is impossible to inject the G-CSF in order to prevent neutropenia.
- Trial name
- NCT01763398
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Yonsei University
Chemotherapy Effect, G-CHOP Chemotherapy
Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs
Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related…
- Conditions
- Chemotherapy Effect, G-CHOP Chemotherapy, R-CHOP Chemotherapy
- Trial name
- Melodia (NCT05350930)
- Testing
- Assessment of patient satisfaction regarding tele-consultation, Literacy questionnaire, Collection of socio-demographic characteristics
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Hospices Civils de Lyon
Lymphoma, Non-Hodgkin
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone…
- Trial name
- NCT02055820
- Testing
- Venetoclax, Cyclophosphamide, Obinutuzumab
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus…
- Trial name
- NCT01287741
- Testing
- Rituximab, Obinutuzumab, Cyclophosphamide
- Where
- 235 sites in United States, Argentina and 27 more
- Volunteers
- 1,418 people
- Sponsor
- Hoffmann-La Roche